CENTESSA PHARMACEUTICALS-ADR (CNTA) Stock Balance Sheet
NASDAQ:CNTA - Nasdaq - US1523091007 - ADR - Currency: USD
| MRQ (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | 105.16M | 383.22M | 128.03M | 393.60M | 595.10M | |||
| Marketable Securities | 179.35M | 98.96M | 128.52M | N/A | N/A | |||
| Receivables | 51.36M | 45.30M | 39.15M | 26.70M | 16.80M | |||
| Other Current Assets | 11.85M | 8.94M | 19.39M | 17.40M | 16.90M | |||
| Total Current Assets | 347.72M | 536.41M | 315.09M | 437.70M | 628.80M | |||
| Non-Current Assets | ||||||||
| PPE Net | 11.46M | 11.76M | 12.95M | 1.20M | 200.00K | |||
| Investments And Advances | 140.40M | N/A | N/A | N/A | N/A | |||
| Other Non-Current Assets | 28.27M | 28.63M | 32.20M | 5.40M | 700.00K | |||
| Total Non-Current Assets | 180.13M | 40.39M | 45.15M | 6.60M | 800.00K | |||
| TOTAL ASSETS | 527.85M | 576.80M | 360.25M | 444.30M | 629.60M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | N/A | 0.00 | |||
| Accrued Expenses | 17.58M | 50.02M | 27.46M | 22.90M | 15.80M | |||
| Accounts Payable | 5.13M | 7.14M | 11.81M | 13.80M | 8.10M | |||
| Other Current Liabilities | 1.49M | 835.00K | 112.00K | 1.60M | 800.00K | |||
| Total Current Liabilities | 24.20M | 58.00M | 39.38M | 38.30M | 24.60M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 109.25M | 108.94M | 75.70M | 69.80M | 75.70M | |||
| Other Non-Current Liabilities | 8.14M | 8.31M | 8.92M | 0.00 | 37.70M | |||
| Total Non-Current Liabilities | 117.40M | 117.25M | 84.62M | 69.80M | 113.50M | |||
| TOTAL LIABILITIES | 141.60M | 175.25M | 124.00M | 108.10M | 138.10M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.01B | -988.70M | -752.95M | -601.90M | -385.70M | |||
| Additional Paid In Capital | 1.40B | 1.39B | 987.42M | 939.30M | 876.30M | |||
| Common Shares | 362.00K | 359.00K | 273.00K | 300.00K | 300.00K | |||
| Other Shareholders' Equity | 2.08M | 4.21M | 1.49M | -1.50M | 700.00K | |||
| Shares Outstanding | 134.14M | 133.22M | 99.21M | 95.22M | 90.40M | |||
| Tangible Book Value per Share | 2.89 | 3.03 | 2.39 | 3.55 | 5.46 | |||
| Total Shareholders' Equity | 386.25M | 401.55M | 236.24M | 336.20M | 491.60M | |||
| TOTAL LIABILITIES AND EQUITY | 527.85M | 576.80M | 360.25M | 444.30M | 629.60M | |||
| Statistics | ||||||||
| Debt/Equity | 0.28 | 0.27 | 0.32 | 0.21 | 0.15 | |||
| Current Ratio | 14.37 | 9.25 | 8.00 | 11.43 | 25.56 | |||
| Return On Assets (ROA) | -42.41% | -40.87% | -41.94% | -48.66% | -60.53% | |||
| Return On Equity (ROE) | -57.95% | -58.71% | -63.95% | -64.31% | -77.52% | |||
All data in USD , ROIC based on taxRate of 0.21